Naturalistic, Prospective Study of Glaucoma and Ocular Hypertension Treatment in France: Strategies, Clinical Outcomes, and Costs at 2 Years

Abstract

Insufficient IOP control and adverse drug reactions are the two main reasons for changing first-line treatment in patients with POAG or OH. After 2 years, second-line treatment with latanoprost, as monotherapy or combined with timolol, provides superior safety and persistency to treatment at an acceptable cost.

Persistency rates for prostaglandin and other hypotensive eyedrops: population‐based study using pharmacy claims data

“…Similar to previous studies that have compared at least one prostaglandin with other hypotensive eyedrops, our study reinforces that persistency with prostaglandins is higher than that achieved with beta‐blockers, alpha‐agonists or carbonic anhydrase inhibitors 2–4,7,14,15 . However, our study extends the findings from these previous studies by also showing that persistency with the dorzolamide‐timolol combination, which was not examined in these studies, was similar to that achieved with two of the prostaglandins, latanoprost and bimatoprost, and higher than that achieved with the third prostaglandin examined, travoprost.…”

Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency

“…A leading study done three years ago that prospectively looked at the expenditure involved in treating glaucoma and OHT over a two-year period in France found that the average daily cost for latanoprost monotherapy was similar to patients who failed beta-blocker monotherapy and that both drugs together did not cost more than therapeutic combinations without latanoprost (Rouland et al 2005b). There are other cost-effectiveness models that compare one of the newer prostaglandin analogues with older medications or with one another.…”

Efficiency of Glaucoma Drug Regulation in 5 European Countries

“…Treatment switches are now known to be associated with more medical visits, more laboratory examinations, and greater need for personal care; 9-15,27 hence, total healthcare costs are higher. An association between PGA medication and fewer interventions by laser therapy and filtering surgery [16][17][18][19][20][21][22][23][24][25][26] is well documented at a population level. Therefore, the impact of restricting first-line treatment to PGAs should be evaluated not only in terms of the drug budget but should encompass all resources dedicated to glaucoma care.…”